EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc. (NYSE: BNT) (“Bentley” or the “Company”) announced today that it notified the New York Stock Exchange (the “NYSE”) of its intent to delist its common stock, par value $0.02 per share, from the NYSE immediately following the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 31, 2008, by and among Bentley, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) (“Teva”) and Beryllium Merger Corporation (the “Merger Agreement”).
